

# When Less is More: Deprescribing Medications

Robert B. Allison, II DO

March 2, 2019

## OBJECTIVES

- ✓ Describe polypharmacy, the individuals at risk, and the potential adverse drug events related to multiple medications
- ✓ Review deprescribing myths and pitfalls
- ✓ Recognize common medications that can be deprescribed
- ✓ Apply deprescribing algorithms for clinical use




## POLYPHARMACY

### DEFINING POLYPHARMACY

Describe what water tastes like

Define sleep

Explain left vs right



## DEFINING POLYPHARMACY

- ▶ Concurrent use of multiple medications – American Journal of Medicine 1985
- ▶ The use of two or more medications... - Drugs & Aging 2010
- ▶ Polypharmacy was defined as the concurrent use of five or more medications – Current Gerontology and Geriatrics Research 2017

## POLYPHARMACY

Multiple medications for adults  $\geq 65$  years old

- ▶ 40% take 5 to 9 medications
- ▶ 18% take 10+

Adverse Drug Events (ADE) occur because of:

- ▶ Age-related physiological changes
- ▶ a greater degree of frailty
- ▶ Multimorbidity
- ▶ Polypharmacy

*Emergency Hospitalizations for Adverse Drug Events in Older Americans NEMJ 2011*

# Adverse Drug Events

Adverse drug events are a direct consequence of clinical care

Older adults are 7 times more likely to have adverse drug event than younger patients



# Adverse Drug Events

**Table 2. National Estimates of Emergency Hospitalizations for Adverse Drug Events in Older U.S. Adults, According to Therapeutic Category, 2007–2009.\***

Therapeutic Category	Annual National Estimate of Hospitalizations (N=99,628)		Proportion of Emergency Department Visits Resulting in Hospitalization
	no.	% (95% CI)	%
Hematologic agents	42,104	42.3 (35.5–49.0)	44.6
Endocrine agents	22,726	22.8 (16.7–28.9)	42.1
Cardiovascular agents	9,800	9.8 (7.1–12.5)	42.3
Central nervous system agents	9,621	9.7 (7.6–11.8)	32.2
Antiinfective agents	3,759	3.8 (2.6–4.9)	17.4
Antineoplastic agents	2,882 <sup>†</sup>	2.9 (0.9–4.9) <sup>†</sup>	51.0
Other agents	3,211	3.2 (2.6–3.8)	15.0
Medications not stated or not known	957	1.0 (0.5–1.5)	20.6
Medications in more than one therapeutic category	4,568 <sup>†</sup>	4.6 (2.7–6.5)	41.2

Emergency Hospitalizations for Adverse Drug Events in Older Americans NEMJ 2011

# Adverse Drug Events

**Table 3. National Estimates of Emergency Hospitalizations for Common Manifestations of Adverse Drug Events in Older U.S. Adults, 2007–2009.\***

Endocrine agents			
Cardiovascular agents			1.5
Electrolyte or fluid	Antiinfective agents		
Central nervous system agents			20.0
Fall or other injury		14.9 (9.1–20.8)	36.4
Altered mental status		42.2 (37.7–46.7)	52.1
Neuropsychiatric or other neurologic effect		9.7 (5.2–14.2)	27.7
Dizziness, syncope, weakness, dyspnea, or respiratory distress		12.1 (7.8–16.4)	23.0
Gastrointestinal effect		9.9 (4.9–14.9)	23.9
Elevated INR, abnormal laboratory values, or drug toxicity not otherwise described		23.7 (16.8–30.6)	59.5


*Emergency Hospitalizations for Adverse Drug Events in Older Americans NEMJ 2011*

# Adverse Drug Events

Most Commonly Implicated Medications Resulting in Hospitalizations:

- ✓ Warfarin (33.3%)
- ✓ Insulins (14%)
- ✓ Oral Anti-platelet Agents (13%)
- ✓ Oral Hypoglycemics (11%)
- ✓ Opioid analgesics (4.8%)
- ✓ Antibiotics (4.2%)
- ✓ Digoxin (3.5%)
- ✓ Antineoplastic agents (3.3%)

*Emergency Hospitalizations for Adverse Drug Events in Older Americans NEMJ 2011*



## DEPRESCRIBING MYTHS AND PITFALLS

### MYTHS

#### PROVIDER CENTERED

- ▶ “It can come off looking like you no longer care about the patient, you know, “You’re old enough to die now so it doesn’t really matter”
- ▶ We need more research, more collaborations
- ▶ “Education would be very helpful for us, in sort of just giving us more confidence”
- ▶ “The reason you don’t stop things is you think they [specialists] know better than you”

#### PATIENT CENTERED

- ▶ There are people who see medication as the barrier between them and the grave
- ▶ “a pill for every ill”
- ▶ “You need some funded time with the patient so that you can bring the patient in and say “This is a special appointment that’s not to talk about your current medical problems, it’s specifically about managing your medicines better.”

Swimming against the tide. Ann Fam Med 2017



A silhouette of a person walking a tightrope across a dark, deep chasm. The background is dark and moody, with the tightrope stretching across the frame.

## PITFALLS

- ▶ Medication management and prescribing has been a cornerstone of medicine from its inception
- ▶ Deprescribing is not commonly taught, it's time-consuming, and it can come with inherent risks for both providers and for their patients
- ▶ Physicians want to maintain a relationship with both their patients and colleagues
- ▶ In some cases, polypharmacy is not synonymous with inappropriate treatment. In several cases, a multi-drug regimen is necessary and appropriate

A group of diverse people, including a woman in the foreground, celebrating with their arms raised in a gesture of triumph. The image is overlaid with blue and red geometric shapes.

## DEPRESCRIBING

## DEPRESCRIBING

- ▶ 1/5 medications commonly taken by older adults may be inappropriate
- ▶ 1/3 prescriptions may be inappropriately used for those living in managed care facilities
- ▶ The *NUMBER* of drugs a patient takes is the single most important predictor of harm




## What is DEPRESCRIBING

A systematic process of identifying and discontinuing drugs when existing or potential harms outweigh existing or potential benefits based on the patient's:

- ▶ Goals of Care
- ▶ Current Level of Functioning
- ▶ Life Expectancy,
- ▶ Values
- ▶ Preferences

Reducing inappropriate polypharmacy the process of deprescribing. JAMA Inter Med. 2015





## DEPRESCRIBING

*“Deprescribing is not about denying effective treatment to eligible patients. It is a positive, patient-centered intervention, with inherent uncertainties, and requires shared decision making, informed patient consent, and close monitoring of effects”*

Reducing inappropriate polypharmacy the process of deprescribing. JAMA Inter Med. 2015

## DEPRESCRIBING

The Process of deprescribing involves:

- ▶ Diagnosing a problem (use of a potentially inappropriate medication)
- ▶ Making a therapeutic decision (withdrawing medication with close follow-up)
- ▶ Altering the natural tendencies of providers in an attempt to reduce the incidence of drug-related adverse events
  - Falls
  - Relieving adverse effects
  - Improving function
  - Preventing premature death

## THE 5 STEPS OF DEPRESCRIBING

1. Reconcile all the medications and the reason for each medication
  - ✓ Prescription
  - ✓ OTC
  - ✓ Supplements
2. Determine the overall harm the medication list poses to the patient
  - ✓ Number of pills
  - ✓ Patient age
  - ✓ Life expectancy / comorbidities
  - ✓ Adherence / cognitive function

Reducing inappropriate polypharmacy the process of deprescribing. JAMA Inter Med. 2015

## THE 5 STEPS OF DEPRESCRIBING

### 3. Assess each drug for its ability to be deprescribed

- ✓ No VALID indication
- ✓ Part of a deprescribing cascade / taper
- ✓ ADE > potential benefit - "Side effect effect"
- ✓ Further need / effectiveness
- ✓ Preventive effect unlikely to confer any patient-oriented benefit based on life expectancy
- ✓ Goals of care / patient preference
- ✓ Drugs are imposing unacceptable treatment burden

Reducing inappropriate polypharmacy the process of deprescribing. JAMA Inter Med. 2015

## THE 5 STEPS OF DEPRESCRIBING

### 4. Prioritize the deprescribing

- ✓ Drugs with greatest harm and least benefit
- ✓ Drugs easiest to discontinue
- ✓ Pills the patient is most willing to discontinue first

Low harm, high benefit

intermediate harm, moderate benefit

High harm, low benefit

Reducing inappropriate polypharmacy the process of deprescribing. JAMA Inter Med. 2015

## EXAMPLES OF DRUGS TO BE DEPRESCRIBED

### Prescriber Ease of Removal

- ▼ Multi-vitamins
- ▼ Iron Supplements
- ▼ Vitamins
- ▼ Supplements
- ▼ Proton Pump Inhibitors
- ▼ Oral hypoglycemics
- ▼ Acetylcholinesterase Inhibitors
- ▼ Antihypertensive
- ▼ Opioids
- ▼ Benzodiazepines
- ▼ Antipsychotics

### Patient Resistance of Removal


- ▲ Opioids
- ▲ Benzodiazepines
- ▲ Acetylcholinesterase Inhibitors
- ▲ Vitamins
- ▲ Supplements
- ▲ Antipsychotics
- ▲ Oral hypoglycemics
- ▲ Antihypertensive
- ▲ PPI
- ▲ Iron Supplements

## THE 5 STEPS OF DEPRESCRIBING

### 5. Implement and monitor deprescribing regimen

- ✓ Develop a management regimen between prescriber and patient
- ✓ Stop 1 medication at a time
- ✓ Ween medications likely to cause withdrawal effects
- ✓ Document the reasons for and outcomes of deprescribing

Reducing inappropriate polypharmacy the process of deprescribing. JAMA Inter Med. 2015



Research

JAMA | Original Investigation

### Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain

**CONCLUSIONS AND RELEVANCE** Treatment with opioids was not superior to treatment with nonopioid medications for improving pain-related function over 12 months. Results do not support initiation of opioid therapy for moderate to severe chronic back pain or hip or knee osteoarthritis pain.

Erin E. Krebs  
Kurt Kroemer

The SPACE randomized clinical trial. JAMA. 2018

**Vitamin D Supplementation in Adults: Common Questions**

Michael L. Lefevre, MD, MSP  
Nicholas M. Lefevre, MD

The USPSTF found adequate evidence that treating vitamin D deficiency does not reduce risk of cancer, type 2 diabetes mellitus, or death in community-dwelling adults, or fractures in persons not at high risk of fractures. Evidence is insufficient for other outcomes, including psychosocial and

Physicians should not measure 25-OH-D levels or prescribe vitamin D supplementation in the treatment of depression, fatigue, osteoarthritis, or chronic pain.

Randomized controlled trials do not show benefits for fractures commonly treated with vitamin D. Skeletal conditions have been inadequately studied.

Best available evidence. C = consensus, GRADE-CEREP evidence rating system, go to <http://www.uspstf.org>

Vitamin D screening and supplementation in community-dwelling adults. Am Fam Physician. 2018

**VIEWPOINT**

## Vitamin and Mineral Supplements

### What Clinicians Need to Know

JoAnn E. Manson, MD, DrPH  
Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston,

- ▶ Most randomized clinical trials of vitamin and mineral supplements have not demonstrated clear benefits for primary or secondary prevention of chronic diseases not related to nutritional deficiency
- ▶ High doses of  $\beta$ -carotene, folic acid, vitamin E, or selenium—may have harmful effects, including increased mortality, cancer, and hemorrhagic stroke
- ▶ Multivitamin/multimineral supplementation is not recommended for generally healthy adults
- ▶ “Cocoa Supplement and Multivitamin Outcome Study” (COSMOS) to conclude October 2020

Vitamin and mineral supplements: what clinicians need to know. JAMA. 2018

## Case 1

67yo male with h/o HTN, HLD, DMII, BPH, and GERD presents for CDM. He states he wants to get off of some of his medications because he just retired, went on Medicare insurance, and found out they don't cover some of his old medications.

### Medications

- Chlorthalidone 50mg daily
- Lisinopril 20mg daily
- Metformin 1000mg BID
- Atorvastatin 40mg daily
- Glyburide 10mg BID
- Detrol XL 4mg daily
- Nexium 40mg daily
- Aspirin 81mg daily
- Potassium Chloride 20meq BID
- Selenium daily
- Multivitamin daily

## Case 1

He does report he has been trying to eat better, started walking with his wife at night, and has cut back on the alcohol since retiring. Unfortunately, he has been getting dizzy at night and finds that he is clammy when he wakes up to go to the bathroom. He has 3-4 episodes of nocturia / night. He also finds that he's constipated. Otherwise, he denies any fevers, chills, CP, SOB, nausea, abdominal pain, diarrhea, constipation, or daytime urinary frequency.

### Exam

- Vitals: 112/72, HR 78, RR 12, 98.6
- General: WD, WN, NAD
- HEENT: NC/AT, EOMI, PERRLA, Oral pharynx appears dry
- Cardiac: RRR, no M/R/G
- Lungs: CTA bilat, no W/R/R
- Abdomen: BS x 4, soft, NT/ND. No R/G/R
- Ext: No clubbing, cyanosis, or edema
- DRE: Appropriate sphincter tone, symmetrically enlarged prostate without nodule



### Case 1

138	100	20	89
3.0	27	0.9	

A1c: 5.9

PSA: 1.20

### Case 1

How do we start with deprescribing?

- 1) Reconcile all the medications and the reason for each medication.
- 2) Determine the overall harm the medication list poses to the patient.
- 3) Assess each drug for its ability to be deprescribed.
- 4) Prioritize the deprescribing.
- 5) Implement and monitor deprescribing regimen.

## Case 1

### Medications

Chlorthalidone 50mg daily →  
 Lisinopril 20mg daily →  
 Metformin 1000mg BID →  
 Glyburide 10mg BID →  
 Atorvastatin 40mg daily →  
 Tolterodine XL 4mg daily →  
 Esomeprazole 40mg daily →  
 Aspirin 81mg daily →  
 Potassium Chloride 20meq BID →  
 Selenium daily →  
 Multivitamin daily →

### Indications

Hypertension  
 Hypertension  
 Diabetes  
 Diabetes  
 Hyperlipidemia  
 Overactive Bladder?  
 GERD – no Barrett's or esophagitis  
 Primary ASCVD prevention  
 hypokalemia 2° to Chlorthalidone?  
 ???  
 ???

## Case 1

### Medications

✓ Chlorthalidone 50mg daily →  
 ✓ Lisinopril 20mg daily →  
 ✓ Metformin 1000mg BID →  
 ✓ Glyburide 10mg BID →  
 ✓ Atorvastatin 40mg daily →  
 ✓ Tolterodine XL 4mg daily →  
 ✓ Esomeprazole 40mg daily →  
 ✓ Aspirin 81mg daily →  
 ✓ Potassium Chloride 20meq BID →  
 ✓ Selenium daily →  
 ✓ Multivitamin daily →

### Indications

Hypertension  
 Hypertension  
 Diabetes  
 Diabetes  
 Hyperlipidemia  
 Overactive Bladder?  
 GERD – no Barrett's or esophagitis  
 Primary ASCVD prevention  
 hypokalemia 2° to Chlorthalidone?  
 ???  
 ???

## Case 1

Where do we start with deprescribing?

MedStopper is a deprescribing resource for healthcare professionals and their patients.

- 1 Frail elderly?
- 2 Generic or Brand Name:
- 3 Select Condition Treated:

Generic Name	Brand Name	Condition Treated	Add to MedStopper

Previous Next

## Case 1

Assessment / Plan:

1. Diabetes Mellitus – well controlled. Likely getting hypoglycemic at night given tight glycemic control. Deprescribe Glyburide. Continue Metformin. Recheck A1c 3mos
2. Hypertension – continue lisinopril for primary and secondary prevention. Consider stopping chlorthalidone and potassium supplement given well controlled hypertension and hypokalemia on BMP. Repeat BMP 1wk
3. GERD – No history of Barrett’s or esophagitis. Consider deprescribing esomeprazole
4. BPH – No indication for over-active bladder treatment. Pt also experiencing likely anticholinergic side effects from Detrol LA. Consider deprescribing tolterodine LA
5. Primary ASCVD prevention – Continue atorvastatin and ASA. No indication for supplement use. Deprescribe multivitamin and selenium

Other

POCKET GUIDE: TAPERING OPIOIDS FOR CHRONIC PAIN\*

Follow up regularly with patients to

Criteria for potentially

**CLINICAL INVESTIGATION**

**American Geriatrics Society 2019 Updated AGS Beers Criteria<sup>®</sup> for Potentially Inappropriate Medication Use in Older Adults**

*By the 2019 American Geriatrics Society Beers Criteria<sup>®</sup> Update Expert Panel\**

Am

Potentially inappropriate Medication Use in Older Adults


By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel

GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN

\*Recommendations focus on pain lasting longer than 3 months or past the time of normal tissue healing, outside of active cancer treatment, palliative care, and end-of-life care.

**OBJECTIVES**

- ✓ Describe polypharmacy, the individuals at risk, and the potential adverse drug events related to multiple medications
- ✓ Review deprescribing myths and pitfalls
- ✓ Recognize common medications that can be deprescribed
- ✓ Apply deprescribing methods clinically



QUESTIONS?

## RESOURCES

American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. *JAGS*. 2015. 1-20

American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *JAGS*. 2019. 1-21

Budnitz, DS, et al. Emergency hospitalizations for adverse drug events in older americans. *N Engl J Med* 2011;365:2002-12

Krebs, EE, et al. Pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain. The SPACE randomized clinical trial. *JAMA*. 2018;319(9):872-882

LeFevre, ML, LeFevre, NM. Vitamin D screening and supplementation in community-dwelling adults: common questions and answers. *Am Fam Physician*. 2018;97(4):254-260

Mahony, D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age and Aging*. 2015. 44. 213-218

Mason, JE, Bassuk, SS. Vitamin and mineral supplements: what clinicians need to know. *JAMA*. 2018. 319(9):859-860

Moyer VA; US Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014; 160(8):558-564.

Scott, IA, et al. Reducing inappropriate polypharmacy the process of deprescribing. *JAMA Intern Med*. 2015;175(5):827-834

Vrettos, I, et al. Disease linked to polypharmacy in elderly patients. *Current gerontology and geriatric research*. 2017. 1-5. <https://doi.org/10.1155/2017/4276047>

Wallis, KA. Swimming against the tide: primary care physicians' views on deprescribing in everyday practice. *Ann Fam Med* 2017; 15(4):341-46